Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Overview of attention for article published in Journal of Clinical Oncology, January 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 13 news outlets
twitter: 50 X users
patent: 3 patents

facebook: 1 Facebook page
reddit: 1 Redditor
guideline: 1 clinical guideline source

Readers on

mendeley: 319 Mendeley

So far, Altmetric has seen 15 news stories from 13 outlets.

Eprenetapopt and azacitidine combination yields high response rates in TP53-mutant MDS

Pediatric News , 28 Aug 2024

Clinical Edge Journal Scan March 8, 2021|Hematology and Oncology March 2021: Clinical Edge Journal Scans (1 of 10) Key clinical…

Clinical Challenges: Treating TP53-Mutated Acute Myeloid Leukemia

MedPage Today, 16 May 2022

Clinical Challenges > TCTM: AML "It's of paramount importance that we do better for these patients," expert notes by Mike…

Targeting the Untargetable: Novel Agents in Acute Myeloid Leukemia

Pharmacy Times, 14 Dec 2021

Pharmacists have an important role in the optimization of AML therapies. Acute myeloid leukemia (AML) is the most common acute…

Next-generation sequencing to impact all aspects of care for myelodysplastic syndrome

Healio.com, 03 Nov 2021

November 03, 2021 3 min read Source/Disclosures Published by: Source: Sallman DA.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 11 additional news stories.